RAD140

RAD140‏‎ (also known as Testolone) is a Selective Androgen Receptor Modulator (SARM) that is currently under development by Radius Health Inc. for potential therapeutic applications. It is being researched for its potential use in the treatment of cancer and muscle wasting disorders.

History

RAD140 was first discovered and developed by Radius Health, a pharmaceutical company. The company's primary goal was to create a drug that could provide the benefits of testosterone without the associated side effects. This led to the development of RAD140, which is designed to selectively bind to androgen receptors in the body.

Mechanism of Action

RAD140 works by selectively binding to androgen receptors in the body. Unlike other SARMs, it does not have an affinity for other steroid hormone receptors. This selective binding is believed to reduce the risk of side effects commonly associated with steroids.

Potential Therapeutic Applications

RAD140 is currently being researched for its potential therapeutic applications. Some of these include:

• Cancer Treatment: RAD140 is being studied for its potential use in the treatment of breast cancer. It is believed to inhibit the growth of cancer cells by blocking the effects of estrogen on these cells.

• Muscle Wasting Disorders: RAD140 may also be beneficial in the treatment of muscle wasting disorders. It is believed to promote muscle growth and strength without the side effects associated with anabolic steroids.

Side Effects

As RAD140 is still under research, its side effects are not fully known. However, some studies suggest that it may cause changes in mood, hair loss, and suppression of natural testosterone production.

Legal Status

RAD140 is not approved by the Food and Drug Administration (FDA) and is therefore not legal for use in dietary supplements. It is also listed as a prohibited substance by the World Anti-Doping Agency (WADA).

See Also

• Selective Androgen Receptor Modulator
• Androgen receptor
• Radius Health Inc.